What Is MOTS-C? A Complete Guide to the Mitochondrial-Derived Peptide

MOTS-C is a small peptide encoded within mitochondrial DNA and studied for its possible role in cellular metabolism, stress adaptation and communication between mitochondria and the rest of the cell.

It contains 16 amino acids and belongs to a developing group of signalling molecules known as mitochondrial-derived peptides.

Unlike most known human peptides, which are encoded by DNA inside the cell nucleus, MOTS-C originates from a short sequence located within the mitochondrial genome.

This unusual origin has made MOTS-C an important research tool for investigating whether mitochondria do more than produce energy.

Research now suggests that mitochondria can generate signals capable of influencing:

• Glucose metabolism

• Insulin sensitivity

• Cellular stress responses

• Skeletal-muscle function

• Gene expression

• Inflammation

• Exercise adaptation

• Age-associated physical decline

The original MOTS-C study found that the peptide improved glucose regulation and reduced diet-induced weight gain and insulin resistance in mice.

Later research found that exercise increased endogenous MOTS-C levels in humans and that experimental MOTS-C treatment improved physical performance in young, middle-aged and older mice.

These findings have led to descriptions of MOTS-C as an “exercise mimetic,” a “mitochondrial hormone” and an “anti-ageing peptide.”

Each description requires caution.

MOTS-C has produced exercise-related and metabolic effects in experimental models, but it has not been shown to reproduce the complete benefits of physical activity in humans. Most intervention evidence still comes from cells and animals, and MOTS-C is not an authorised UK medicine.

This guide examines what MOTS-C is, how it may work, what has actually been demonstrated and which claims remain unproven.

MOTS-C quick facts

MOTS-C was first described in 2015 as a mitochondrial-encoded peptide that influenced skeletal-muscle metabolism through pathways involving folate metabolism, purine synthesis and AMPK.

What are mitochondria?

Mitochondria are structures found within most human cells.

They are often called the cell’s powerhouses because they convert energy from nutrients into adenosine triphosphate, or ATP.

ATP provides usable energy for processes including:

• Muscle contraction

• Nerve signalling

• Protein production

• Active transport

• Cell repair

• Immune function

However, mitochondria do much more than generate ATP.

They also participate in:

• Calcium regulation

• Heat production

• Oxidative-stress signalling

• Cell death

• Fatty-acid metabolism

• Amino-acid metabolism

• Steroid production

• Immune signalling

• Adaptation to stress

Mitochondria retain a small genome of their own.

Human mitochondrial DNA contains 37 conventionally recognised genes, most of which encode proteins or RNA molecules required for mitochondrial energy production.

For many years, regions outside these conventional genes were assumed to have little or no protein-coding function.

The discovery of mitochondrial-derived peptides challenged that view.

What are mitochondrial-derived peptides?

Mitochondrial-derived peptides are small signalling molecules encoded by short open-reading frames within mitochondrial DNA.

An open-reading frame is a DNA sequence with the potential to encode a peptide or protein.

Known mitochondrial-derived peptides include:

• Humanin

• MOTS-C

• Small humanin-like peptides, or SHLPs

• SHMOOSE

These molecules are being studied as possible signals through which mitochondria communicate with:

• The cell nucleus

• Neighbouring cells

• Distant tissues

• The circulation

This communication is sometimes described as mitochondrial retrograde signalling.

Conventional cellular signalling often flows from nuclear DNA to proteins and then towards the mitochondria.

Retrograde signalling describes information travelling in the opposite direction: mitochondria signalling their metabolic or stress status back to the nucleus.

MOTS-C appears to participate in this process.

What does MOTS-C stand for?

MOTS-C stands for:

Mitochondrial open-reading-frame of the 12S ribosomal RNA type-c

The name reflects the location of its proposed coding sequence within mitochondrial DNA.

The peptide is encoded within a short open-reading frame located in the region associated with mitochondrial 12S ribosomal RNA.

The “C” identifies the particular open-reading frame selected during the researchers’ original sequence analysis.

MOTS-C should not be confused with:

• MOTS as a general abbreviation

• A conventional protein encoded by nuclear DNA

• A fragment of an established metabolic hormone

• A modified version of GLP-1

• A stimulant

It is a distinct 16-amino-acid mitochondrial-derived peptide.

What is the amino-acid sequence of MOTS-C?

The reported human MOTS-C sequence is:

MRWQEMGYIFYPRKLR

This sequence contains 16 amino acids.

The precise sequence matters because even one amino-acid substitution can affect:

• Molecular shape

• Stability

• Cellular uptake

• Target binding

• Metabolism

• Biological activity

A naturally occurring mitochondrial DNA variant can alter the MOTS-C sequence in some populations.

This variant has been studied in relation to type 2 diabetes, body composition and physical activity, illustrating how mitochondrial genetics may influence MOTS-C biology.

How was MOTS-C discovered?

MOTS-C was reported in 2015 by researchers investigating short potential coding sequences within mitochondrial DNA.

The research group identified a peptide encoded within the mitochondrial 12S ribosomal RNA region and demonstrated its presence using molecular and analytical methods.

The initial study investigated the effects of MOTS-C in:

• Cultured cells

• Skeletal muscle

• Mice fed a high-fat diet

• Older mice with impaired insulin sensitivity

Researchers reported that MOTS-C influenced folate and purine metabolism, activated AMPK and increased glucose use in skeletal muscle.

In mice, experimental treatment reduced high-fat-diet-associated weight gain and improved insulin sensitivity.

The study established MOTS-C as a possible mitochondrial signal involved in metabolic homeostasis rather than as a conventional component of the energy-production machinery.

Where is MOTS-C produced?

MOTS-C has been detected in several tissues and in the circulation.

Skeletal muscle appears to be particularly important because it is:

• A major site of glucose disposal

• Highly dependent on mitochondrial function

• Responsive to exercise

• Central to whole-body insulin sensitivity

• A large endocrine and metabolic organ

MOTS-C has also been investigated in relation to:

• Fat tissue

• The liver

• The heart

• Bone

• The brain

• The kidneys

• Immune cells

The tissue in which MOTS-C is detected is not necessarily the same tissue in which it was produced.

Peptides can be released, transported and taken up elsewhere.

Researchers are still establishing how MOTS-C is translated, processed, exported and distributed within the body.

How can mitochondrial DNA produce MOTS-C?

The translation of MOTS-C raises an unusual biological question.

Mitochondria and the cell cytoplasm use slightly different genetic codes.

The proposed MOTS-C sequence can be produced when its RNA is interpreted using the standard nuclear or cytoplasmic genetic code. Under the mitochondrial code, one of its codons would function as a stop signal.

This suggests that the RNA may need to leave the mitochondrion and be translated by ribosomes in the cytoplasm.

However, the complete mechanism has not been established.

Important unanswered questions include:

• How the RNA exits the mitochondrion

• Where translation occurs

• How translation is regulated

• How the peptide is processed

• How MOTS-C enters or leaves cells

• Which proteins transport it

• Whether all measured forms represent intact active peptide

MOTS-C biology therefore remains an active area of mitochondrial genetics research.

How is MOTS-C thought to work?

MOTS-C does not appear to act through one clearly established cell-surface receptor.

Instead, research suggests that it influences cellular metabolism and stress adaptation through several mechanisms.

The best-studied pathways include:

• Folate metabolism

• Purine synthesis

• AICAR accumulation

• AMPK activation

• Glucose uptake

• Nuclear translocation

• Stress-responsive gene expression

• CK2 signalling

• Skeletal-muscle metabolic adaptation

These mechanisms are connected rather than independent.

MOTS-C and folate metabolism

Folate is required for one-carbon metabolism, a network of reactions involved in:

• DNA synthesis

• Amino-acid metabolism

• Methylation

• Purine production

• Cellular growth

The original MOTS-C study found that the peptide disrupted part of the folate cycle.

This reduced the availability of intermediates needed for the de novo purine synthesis pathway.

Purines are building blocks used to produce molecules including:

• ATP

• GTP

• DNA

• RNA

When purine synthesis is interrupted at a specific stage, an intermediate known as AICAR can accumulate.

AICAR is relevant because it can activate AMPK.

This provided the first proposed connection between MOTS-C and cellular energy sensing.

What is AMPK?

AMPK stands for AMP-activated protein kinase.

It is a cellular enzyme complex that helps detect and respond to low-energy conditions.

AMPK activity can increase when the cell’s balance shifts away from high-energy ATP and towards lower-energy molecules such as AMP.

Once activated, AMPK generally promotes processes that generate or conserve energy.

These may include:

• Increasing glucose uptake

• Increasing fatty-acid oxidation

• Supporting mitochondrial adaptation

• Reducing energy-intensive biosynthesis

• Improving cellular stress resistance

• Influencing autophagy

Exercise is one of several conditions capable of activating AMPK in skeletal muscle.

This is part of the reason MOTS-C has been compared with exercise.

However, AMPK activation is not unique to MOTS-C, and activating one exercise-responsive pathway does not reproduce the complete physiological effects of exercise.

Does MOTS-C activate AMPK?

The original study reported increased AMPK activation following MOTS-C exposure.

Researchers proposed the following simplified sequence:

1. MOTS-C alters folate metabolism.

2. De novo purine synthesis is partially restricted.

3. AICAR accumulates.

4. AMPK activity increases.

5. Skeletal-muscle glucose uptake and metabolic adaptation increase.

Later work also found that AMPK was involved in the movement of MOTS-C into the cell nucleus during metabolic stress.

The relationship may not be completely linear.

More recent experiments have identified other possible targets, including casein kinase 2, or CK2, and suggest that some effects could depend on tissue context and interaction with broader metabolic networks.

MOTS-C should therefore not be reduced to “an AMPK peptide.”

MOTS-C and nuclear translocation

One of the most important later discoveries was that MOTS-C can move into the cell nucleus under metabolic stress.

The nucleus contains most of the cell’s DNA and controls gene expression.

In a 2018 study, metabolic stress caused MOTS-C to move from the cytoplasm into the nucleus through an AMPK-dependent process.

Inside the nucleus, MOTS-C interacted with stress-responsive transcription factors and influenced the expression of nuclear genes.

These included genes involved in:

• Antioxidant responses

• Metabolism

• Cellular protection

• Stress adaptation

• Protein quality control

This finding provided a direct example of a mitochondrial-encoded peptide affecting nuclear gene expression.

It supports the idea that MOTS-C acts as a messenger between mitochondrial status and the wider cell.

It does not mean that externally administered MOTS-C safely “rewrites” or “resets” human genes.

Does MOTS-C change DNA?

MOTS-C has been reported to influence gene expression, not to rewrite the underlying DNA sequence.

These are very different processes.

Gene expression determines how strongly particular genes are used to produce RNA and proteins.

It can change in response to:

• Exercise

• Nutrition

• Hormones

• Sleep

• Temperature

• Illness

• Cellular stress

A temporary change in gene expression does not mean that a person’s genetic code has been altered.

Claims that MOTS-C “repairs mitochondrial DNA” or “reprograms the genome” go beyond current evidence.

MOTS-C and CK2

Research published in 2024 identified casein kinase 2, or CK2, as a possible direct molecular target of MOTS-C.

CK2 is a protein kinase involved in numerous cellular processes, including:

• Cell survival

• Growth

• Metabolism

• Protein regulation

• Stress responses

The researchers reported that MOTS-C could bind to and activate CK2 in a tissue-dependent manner.

In experimental systems, this interaction was associated with changes in:

• Muscle glucose uptake

• Muscle mass

• Metabolic signalling

This study broadens the proposed mechanism beyond AMPK alone.

Further independent work is needed to determine how important CK2 is in humans and whether it explains all or only some MOTS-C effects.

MOTS-C and glucose metabolism

Glucose is a major fuel for skeletal muscle.

After a meal, insulin helps stimulate glucose movement from the bloodstream into muscle and other tissues.

When muscle becomes less responsive to insulin, the pancreas may need to produce more insulin to maintain normal blood glucose.

This state is known as insulin resistance.

The original MOTS-C experiments found increased glucose uptake and glucose use within muscle-related models.

In mice, MOTS-C improved the response to glucose and insulin under conditions involving:

• High-fat feeding

• Age-associated insulin resistance

• Metabolic stress

Researchers proposed that MOTS-C helped skeletal muscle dispose of glucose through AMPK-related pathways, including mechanisms that were at least partly independent of conventional insulin signalling.

This possibility is scientifically important because impaired skeletal-muscle glucose uptake is a major feature of type 2 diabetes.

However, improved glucose regulation in mice does not establish MOTS-C as a diabetes treatment in humans.

What is insulin sensitivity?

Insulin sensitivity describes how effectively tissues respond to insulin.

When insulin sensitivity is high, a relatively small amount of insulin may produce an appropriate glucose-lowering response.

When insulin sensitivity is reduced, more insulin is required to achieve the same effect.

Factors influencing insulin sensitivity include:

• Genetics

• Body-fat distribution

• Physical activity

• Muscle mass

• Sleep

• Age

• Diet

• Medication

• Hormones

• Inflammation

• Liver fat

• Mitochondrial function

MOTS-C research has focused heavily on insulin sensitivity because skeletal muscle and mitochondria play central roles in glucose metabolism.

Does MOTS-C improve insulin sensitivity in humans?

This has not yet been established through a completed, adequately powered therapeutic trial.

Human studies have reported associations between naturally circulating MOTS-C and metabolic measurements, but the results are not completely consistent.

For example, one study found similar average MOTS-C levels in lean and obese participants, while relationships with insulin-resistance measurements differed between groups.

Other observational studies have reported lower, higher or unchanged MOTS-C concentrations in different metabolic populations.

These differences may reflect:

• Participant age

• Sex

• Ethnicity

• Mitochondrial genetics

• Fitness

• Disease stage

• Kidney function

• Laboratory methods

• Sample handling

• The antibody or assay used

Observational associations cannot establish that low MOTS-C causes insulin resistance or that increasing it will treat the condition.

A registered human study is now designed specifically to test whether MOTS-C can improve insulin sensitivity and cardiometabolic markers. Until controlled results are available, therapeutic claims remain premature.

Does MOTS-C reduce obesity?

The original 2015 study found that MOTS-C reduced high-fat-diet-induced weight gain in mice.

It also improved insulin sensitivity despite the animals being exposed to a diet designed to produce metabolic dysfunction.

These results are frequently simplified online as proof that MOTS-C “burns fat.”

That interpretation is too strong.

The animal findings may have resulted from a combination of:

• Altered glucose handling

• Increased energy expenditure

• Changes in metabolic flexibility

• Skeletal-muscle activity

• Stress adaptation

• Changes in food or nutrient processing

MOTS-C has not been proven to produce clinically meaningful weight loss in humans.

There are no large, completed human obesity trials comparable with the clinical programmes for medicines such as semaglutide or tirzepatide.

It should not be described as an established weight-management medicine.

Does MOTS-C directly burn fat?

There is insufficient evidence to describe MOTS-C as a direct human fat-burning treatment.

Animal and cellular research suggests that it may influence:

• Fatty-acid metabolism

• Energy expenditure

• Glucose-fat fuel selection

• Mitochondrial function

• Adipose-tissue signalling

However, reduced weight gain in mice does not show that externally administered MOTS-C causes substantial human fat loss.

Terms such as “fat burner” conceal several important distinctions:

• Preventing weight gain is not the same as causing weight loss.

• Mouse energy metabolism differs from human metabolism.

• Experimental exposure may not match real-world exposure.

• Body-weight changes do not reveal whether fat, fluid or lean tissue changed.

• Mechanistic effects may not be large enough to matter clinically.

Is MOTS-C an exercise mimetic?

An exercise mimetic is a substance intended to reproduce selected biological effects of physical activity.

MOTS-C has been described this way because:

• Exercise increases endogenous MOTS-C.

• MOTS-C activates pathways also affected by exercise.

• Experimental treatment improved physical performance in mice.

• It influences skeletal-muscle metabolism.

• It may support adaptation to metabolic stress.

The description is scientifically understandable but easily overstated.

Exercise affects nearly every organ system.

It produces:

• Mechanical loading

• Cardiovascular conditioning

• Increased blood flow

• Neuromuscular adaptation

• Tendon and bone loading

• Improved coordination

• Psychological benefits

• Immune changes

• Mitochondrial adaptation

• Changes in thousands of signalling molecules

No evidence shows that MOTS-C reproduces this complete response.

It is more accurate to describe it as an exercise-responsive mitochondrial peptide with exercise-like effects in experimental models.

Does exercise increase MOTS-C in humans?

Yes, several studies suggest that physical exercise can affect endogenous MOTS-C.

A 2021 study examined young, healthy men completing an acute cycling session.

Researchers reported increased MOTS-C in skeletal muscle and circulation following exercise.

The same paper found that experimental MOTS-C treatment improved treadmill performance in mice of different ages and supported metabolic adaptation in muscle cells.

Another human study reported that acute endurance exercise stimulated circulating mitochondrial-derived peptides, including a trend towards increased MOTS-C.

A 16-week combined aerobic and resistance programme also increased circulating MOTS-C in one subgroup of breast-cancer survivors, although the response differed between the ethnic groups studied.

These findings indicate that MOTS-C may be part of the normal molecular response to physical activity.

They do not prove that injecting synthetic MOTS-C has the same effect as producing it naturally during exercise.

What did the mouse exercise study find?

The 2021 Nature Communications study examined MOTS-C and physical performance in:

• Young mice

• Middle-aged mice

• Older mice

• Very old mice

Experimental MOTS-C treatment improved physical capacity in several age groups.

Researchers reported effects involving:

• Running performance

• Skeletal-muscle metabolism

• Stress-responsive gene expression

• Metabolic flexibility

• Protein homeostasis

Late-life intermittent treatment also improved physical capacity in very old mice.

These findings support research into age-related physical decline.

However, several limitations are important:

• The subjects were mice.

• Treadmill performance is not equivalent to all aspects of human function.

• Treatment exposure may not reflect informal human use.

• Improved performance does not prove longer life.

• Animal healthspan results do not demonstrate human anti-ageing effects.

Does MOTS-C improve endurance?

Experimental evidence suggests that MOTS-C can improve endurance-related performance in mice.

Human evidence is much more limited.

Studies showing that exercise raises a person’s own MOTS-C levels cannot establish that external MOTS-C supplementation improves human endurance.

To prove an ergogenic effect, controlled human trials would need to examine outcomes such as:

• VO₂ max

• Time-trial performance

• Time to exhaustion

• Power output

• Repeated-sprint performance

• Recovery

• Muscle fatigue

• Training adaptation

Trials would also need adequate blinding, placebo controls, participant numbers and safety monitoring.

Those data are not currently sufficient to support reliable performance claims.

Does MOTS-C increase energy?

“Energy” can refer to several different things:

• Cellular ATP production

• Exercise performance

• Wakefulness

• Motivation

• Reduced fatigue

• Metabolic flexibility

MOTS-C research mainly concerns cellular metabolism and physical performance in experimental models.

It is not a conventional stimulant and has not been shown to act like caffeine or amphetamine.

A subjective feeling of increased energy is not the same as demonstrated improvement in mitochondrial ATP production or exercise capacity.

Controlled human data are required before claims about reduced fatigue or increased daily energy can be considered established.

Does MOTS-C increase mitochondrial function?

MOTS-C is involved in mitochondrial-to-nuclear signalling, but it should not automatically be described as increasing every aspect of mitochondrial function.

Experimental studies have reported effects involving:

• Mitochondrial respiration

• Metabolic flexibility

• Stress adaptation

• Glucose oxidation

• Muscle bioenergetics

• Mitochondrial regulatory pathways

A 2026 mouse study reported increased skeletal-muscle respiratory capacity after four weeks of MOTS-C treatment, with the effect depending on an intact AMPK and PGC-1α regulatory pathway.

That study is relevant mechanistic evidence, but it does not yet establish improved mitochondrial function in treated humans.

“Mitochondrial function” is also not a single measurement.

It can include:

• ATP production

• Oxygen consumption

• Membrane potential

• Reactive-oxygen-species production

• Mitochondrial number

• Quality control

• Fuel selection

• Fusion and fission

• DNA integrity

An improvement in one outcome does not mean all mitochondrial processes improve.

MOTS-C and metabolic flexibility

Metabolic flexibility is the ability to switch appropriately between fuel sources.

For example:

• Using more carbohydrate after a meal

• Using more fat during fasting

• Increasing glucose use during intense exercise

• Adjusting metabolism to changes in energy demand

Insulin resistance and metabolic disease can reduce this flexibility.

MOTS-C appears to influence how skeletal muscle selects and processes fuel under metabolic stress.

This may help explain why it has shown different effects depending on:

• Diet

• Age

• Exercise

• Insulin sensitivity

• Cellular energy status

Metabolic flexibility is a useful research concept, but it cannot be inferred reliably from feelings such as increased energy or reduced appetite.

MOTS-C and skeletal muscle

Skeletal muscle is central to MOTS-C research.

It accounts for a large proportion of insulin-stimulated glucose disposal and is one of the body’s largest metabolically active tissues.

Studies suggest MOTS-C may affect:

• Glucose uptake

• Insulin sensitivity

• Mitochondrial metabolism

• Muscle stress responses

• Myostatin signalling

• Muscle mass

• Exercise performance

• Age-associated decline

Animal work found that MOTS-C reduced elevated myostatin-related signalling in diet-induced obese mice.

Myostatin is a protein that restrains muscle growth and can be associated with muscle wasting under some conditions.

This does not establish MOTS-C as a human muscle-building medicine.

Changes in a signalling protein do not automatically produce clinically meaningful hypertrophy, strength or functional improvement.

Does MOTS-C build muscle?

There is no robust human evidence showing that MOTS-C directly builds substantial skeletal muscle.

Experimental studies have reported effects on:

• Muscle glucose uptake

• Myostatin-related pathways

• Muscle mass in animal models

• Exercise capacity

• CK2 signalling

These findings justify further research in sarcopenia and metabolic muscle disease.

Muscle growth in humans depends on factors including:

• Progressive mechanical loading

• Protein intake

• Energy availability

• Hormonal status

• Age

• Sleep

• Genetics

• Training history

MOTS-C should not be described as a substitute for resistance training or adequate nutrition.

MOTS-C and ageing

Ageing is associated with changes in:

• Mitochondrial function

• Muscle mass

• Insulin sensitivity

• Inflammation

• Cellular stress resistance

• Physical performance

• Protein quality control

MOTS-C concentrations and responses may also vary with age.

In mice, MOTS-C improved metabolic and physical outcomes affected by ageing.

This has led to interest in MOTS-C as a possible geroprotective molecule.

A geroprotective intervention is one intended to modify processes associated with ageing and reduce age-related functional decline.

However, there is currently no proof that MOTS-C:

• Extends human lifespan

• Reverses biological age

• Prevents multiple age-related diseases

• Restores young mitochondrial function

• Permanently rejuvenates tissue

Animal healthspan findings are valuable but should not be converted into human longevity claims.

Does MOTS-C extend lifespan?

There is insufficient evidence that MOTS-C extends lifespan.

The major exercise and ageing study reported improved physical capacity and health-related measurements in old mice.

It did not establish human lifespan extension.

Lifespan and healthspan are different.

• Lifespan is how long an organism lives.

• Healthspan is the period spent in relatively good health and function.

An intervention can improve one functional outcome without extending survival.

Definitive longevity research would require:

• Full-lifespan animal studies

• Replication in several models

• Appropriate cancer and disease monitoring

• Long-term human outcome studies

Does MOTS-C reverse ageing?

No controlled human study has shown that MOTS-C reverses ageing.

The phrase may arise from findings involving:

• Older mice

• Age-related insulin resistance

• Exercise performance

• Stress-response pathways

• Mitochondrial signalling

Improving one age-associated measurement is not equivalent to reversing the complex biological process of ageing.

Ageing involves changes across:

• DNA stability

• Epigenetic regulation

• Immune function

• Protein maintenance

• Stem-cell activity

• Hormonal systems

• Organs

• Blood vessels

• The nervous system

• Social and environmental factors

MOTS-C is best described as a peptide being investigated in relation to age-associated metabolic and physical decline.

MOTS-C and inflammation

Metabolic disorders and ageing are often associated with chronic low-grade inflammation.

Preclinical studies suggest MOTS-C may influence inflammatory pathways, including:

• NF-κB-related signalling

• Cytokine production

• Immune-cell activation

• Oxidative stress

• Endothelial inflammation

These effects have been investigated in models involving:

• Obesity

• Vascular injury

• Kidney injury

• Bone loss

• Cardiac stress

• Neuroinflammation

The effects are context dependent.

Inflammation is not universally harmful. It is required for infection control, tissue repair and adaptation to exercise.

Reducing one inflammatory marker does not establish clinical benefit or justify treating MOTS-C as a general anti-inflammatory medicine.

MOTS-C and cardiovascular research

Researchers have investigated MOTS-C in experimental models of:

• Endothelial dysfunction

• Vascular ageing

• Heart injury

• Cardiac remodelling

• Hypertension

• Atherosclerosis

The endothelium is the inner cellular lining of blood vessels.

Healthy endothelial function helps regulate:

• Blood-vessel dilation

• Blood pressure

• Clotting

• Inflammation

• Movement of nutrients and immune cells

Animal studies suggest MOTS-C may support endothelial responses by affecting AMPK, nitric-oxide signalling, oxidative stress and inflammation.

Human evidence is mostly observational.

There is no completed large cardiovascular-outcomes trial demonstrating that MOTS-C prevents heart attacks, strokes or cardiovascular death.

MOTS-C and bone

Mitochondrial metabolism contributes to the function of:

• Osteoblasts, which build bone

• Osteoclasts, which break down bone

• Bone-marrow stem cells

Animal and cellular research has investigated whether MOTS-C influences age-related or hormone-related bone loss.

Some studies report effects on:

• Osteoblast differentiation

• Osteoclast activity

• Bone formation

• Inflammatory bone loss

• Bone-marrow metabolism

These findings are preliminary.

MOTS-C is not an established treatment for osteoporosis, and changes in cell markers cannot replace fracture-outcome trials or bone-density evidence.

MOTS-C and the brain

Mitochondrial dysfunction and metabolic stress are involved in several neurological conditions.

Preclinical MOTS-C research has explored:

• Cognitive function

• Neuroinflammation

• Stress resilience

• Memory

• Brain metabolism

• Ischaemic injury

It remains unclear how much intact MOTS-C crosses the blood-brain barrier under normal conditions.

Animal findings do not establish effectiveness for:

• Alzheimer’s disease

• Parkinson’s disease

• Depression

• Brain injury

• Cognitive ageing

MOTS-C is not an approved neurological treatment.

MOTS-C and kidney research

Kidney cells have high metabolic demands and contain many mitochondria.

Experimental studies have investigated MOTS-C in models of:

• Acute kidney injury

• Diabetic kidney disease

• Fibrosis

• Oxidative stress

• Inflammation

Some animal studies report protective cellular effects.

However, kidney disease can also change the clearance and circulating concentration of peptides.

Observational relationships may therefore reflect impaired elimination rather than beneficial production.

Human kidney-safety and pharmacokinetic data remain inadequate for non-approved systemic use.

MOTS-C and cancer

Cancer cells frequently alter their metabolism and mitochondrial signalling.

MOTS-C has been examined in relation to:

• Cellular growth

• Metabolic stress

• Chemotherapy response

• Circulating biomarkers

• Cancer-associated metabolic changes

Results are not sufficient to describe MOTS-C as an anti-cancer treatment.

A molecule that changes glucose handling, stress adaptation or cell survival could have different effects depending on:

• Cancer type

• Genetic mutations

• Tissue environment

• Disease stage

• Treatment

• Dose

MOTS-C should not be claimed to prevent or treat cancer.

Its long-term effects in people with active or previous cancer require proper clinical investigation.

Human research on naturally occurring MOTS-C

Human MOTS-C research has mainly measured naturally circulating concentrations rather than administering the peptide as a treatment.

Studies have examined MOTS-C levels in relation to:

• Age

• Obesity

• Insulin resistance

• Type 2 diabetes

• Exercise

• Cardiovascular disease

• Kidney disease

• Cancer

• Muscle function

Results have varied.

Some studies report lower MOTS-C in disease, while others find higher concentrations or no meaningful difference.

These inconsistencies may result partly from measurement difficulties.

Why are MOTS-C blood measurements difficult?

MOTS-C is a small peptide present at low concentrations.

Accurate measurement can be affected by:

• Sample collection

• Time before processing

• Storage temperature

• Freeze-thaw cycles

• Protease activity

• Antibody specificity

• Cross-reactivity

• Calibration

• Detection limits

• Whether intact or fragmented peptide is measured

Many studies use laboratory-developed immunoassays.

Different assays may not produce directly comparable values.

Until measurement is more standardised, differences between studies should be interpreted cautiously.

Human exercise research versus human treatment research

It is important to separate two questions.

Does human exercise change natural MOTS-C?

Evidence suggests that it can.

Several studies report changes in circulating or muscle-associated MOTS-C after acute or long-term exercise.

Does externally administered MOTS-C improve human performance or metabolism?

This remains uncertain.

A rise during exercise shows that MOTS-C may participate in the body’s response to exercise.

It does not prove that administering the peptide reproduces that response safely.

The same principle applies to many biological signals.

Exercise changes adrenaline, lactate, interleukins and growth factors, but administering one signal cannot recreate the full exercise response.

Has MOTS-C been tested in human clinical trials?

Human exposure has been limited compared with established medicines.

A modified MOTS-C analogue known as CB4211 entered early clinical development for metabolic disease.

The analogue was designed to preserve or improve selected MOTS-C-related activity while providing pharmaceutical properties suitable for development.

Early-stage studies reportedly assessed safety, tolerability and metabolic effects.

However:

• An analogue is not identical to native MOTS-C.

• Early-phase exposure does not establish effectiveness.

• Publicly available peer-reviewed outcome data remain limited.

• No MOTS-C-based medicine has received UK marketing authorisation.

A separate registered study is designed to evaluate MOTS-C and insulin sensitivity in humans.

Until peer-reviewed results are available, claims of proven human metabolic benefit are not justified.

Is MOTS-C an approved medicine?

No.

MOTS-C is not an authorised medicine in the United Kingdom for:

• Obesity

• Diabetes

• Exercise performance

• Fatigue

• Ageing

• Muscle loss

• Mitochondrial disease

• Cardiovascular disease

There is no approved UK product information establishing:

• A therapeutic dose

• A dosing schedule

• Contraindications

• Drug interactions

• Long-term safety

• Pregnancy safety

• Appropriate monitoring

• A licensed method of administration

Research findings should not be treated as prescribing guidance.

Is MOTS-C prohibited in sport?

Yes.

MOTS-C appears on the World Anti-Doping Agency Prohibited List under non-approved substances or metabolic modulators.

The 2026 Prohibited List took effect on 1 January 2026.

Athletes subject to anti-doping rules are responsible for substances found in their bodies.

The absence of a licensed medicine or established testing standard does not make a substance permitted.

Athletes should use official anti-doping resources and obtain professional advice rather than relying on supplier descriptions.

What adverse effects have been reported?

There is not enough controlled human evidence to define the adverse-effect profile of MOTS-C reliably.

Potential risks must therefore be inferred from:

• Limited early human exposure

• Animal toxicology

• Peptide immunogenicity principles

• Its biological mechanisms

• Product-quality risks

Possible areas of concern include:

• Injection-site reactions

• Allergic or immune reactions

• Altered glucose regulation

• Unintended effects on metabolic pathways

• Interactions with glucose-lowering medication

• Unknown cardiovascular effects

• Unknown effects on cancer biology

• Unknown reproductive effects

• Copper-independent manufacturing impurities

• Contamination or endotoxin exposure

The absence of many published adverse-event reports does not demonstrate safety.

It may simply reflect limited regulated exposure and incomplete surveillance.

Could MOTS-C lower blood glucose?

Preclinical research suggests that MOTS-C can increase glucose uptake and improve insulin sensitivity.

This creates a theoretical possibility of altering blood glucose, particularly when combined with:

• Insulin

• Sulfonylureas

• Other glucose-lowering medicines

• Prolonged fasting

• Intense exercise

• Low carbohydrate intake

The magnitude of this risk in humans is unknown.

A person experiencing symptoms such as sweating, shaking, confusion, weakness or palpitations requires appropriate assessment rather than assuming the symptoms are an expected peptide effect.

Immunogenicity

Peptides can trigger immune responses.

The risk depends on:

• Sequence

• Chemical modifications

• Aggregation

• Impurities

• Route

• Frequency

• Formulation

• Individual immune factors

Possible consequences include:

• Local reactions

• Antibody formation

• Reduced activity

• Altered clearance

• Hypersensitivity

• Cross-reaction with natural peptides

MOTS-C is derived from a naturally occurring human sequence, but this does not remove immunogenicity risk from externally manufactured material.

Manufacturing impurities, aggregation and repeated exposure can change immune recognition.

Product-quality risks

For an experimental peptide, biological uncertainty is only one part of the risk.

Material quality may also vary.

Potential concerns include:

• Incorrect amino-acid sequence

• Truncated peptides

• Oxidised material

• Degradation

• Incorrect quantity

• Residual synthesis chemicals

• Microbial contamination

• Endotoxin

• Aggregation

• Mislabelled products

A high HPLC purity percentage does not establish:

• Correct identity

• Correct peptide content

• Sterility

• Endotoxin control

• Stability

• Human safety

MOTS-C’s small size also means that sequence verification and appropriate mass-spectrometric identity testing are important.

Is MOTS-C stable?

Peptide stability depends on factors including:

• Temperature

• Moisture

• Light

• Oxygen

• pH

• Container materials

• Repeated handling

• Time in solution

MOTS-C may undergo:

• Oxidation

• Hydrolysis

• Aggregation

• Deamidation

• Sequence degradation

The methionine at the beginning of the reported sequence can be susceptible to oxidation.

A change in appearance is not required for degradation to have occurred.

Stability must be demonstrated for a particular formulation and storage condition rather than assumed from the peptide’s name.

Does MOTS-C have a known half-life?

A definitive, widely accepted human half-life for native MOTS-C has not been established in published clinical pharmacokinetic literature.

Online estimates vary, but they are often presented without a traceable human study.

The half-life of:

• Natural circulating MOTS-C

• Synthetic native MOTS-C

• A modified analogue

• MOTS-C in a particular formulation

may differ substantially.

It would therefore be misleading to provide a precise human half-life as an established fact.

Can animal doses be converted into human doses?

Not reliably for unapproved personal use.

Animal doses are sometimes converted using body-surface-area formulas, but this does not establish a safe or effective human dose.

Species differ in:

• Metabolism

• Peptide clearance

• Receptor biology

• Immune responses

• Tissue distribution

• Enzyme activity

First-in-human dosing also requires:

• Toxicology

• Safety margins

• Pharmacokinetic modelling

• Manufacturing controls

• Clinical monitoring

• Regulatory oversight

A mathematical conversion from a mouse paper is not a substitute for this process.

Common myths about MOTS-C

Myth: MOTS-C is exercise in a vial

Fact: It influences some exercise-responsive pathways and improves performance in mice. It has not been shown to reproduce the complete benefits of exercise in humans.

Myth: MOTS-C has been clinically proven to improve human endurance

Fact: Human studies mainly show that exercise changes natural MOTS-C. Controlled treatment evidence remains inadequate.

Myth: MOTS-C is a proven fat burner

Fact: It reduced diet-induced weight gain in mice. Clinically meaningful human fat loss has not been demonstrated.

Myth: MOTS-C reverses ageing

Fact: It improved selected metabolic and physical outcomes in older mice. It has not reversed human ageing.

Myth: Activating AMPK guarantees weight loss

Fact: AMPK is one part of a complex metabolic network. Pathway activation does not guarantee a visible clinical outcome.

Myth: MOTS-C directly repairs mitochondrial DNA

Fact: It participates in mitochondrial-to-nuclear signalling. Direct repair of mitochondrial DNA has not been established.

Myth: Natural mitochondrial origin makes it safe to inject

Fact: External administration changes concentration, route, timing and exposure. Safety requires controlled human evidence.

Myth: An exercise-induced peptide must be safe for athletes

Fact: MOTS-C is prohibited under anti-doping rules.

Myth: No reported long-term side effects means it is safe

Fact: Long-term human data are limited, so uncommon or delayed risks may not yet be known.

Frequently asked questions

What is MOTS-C?

MOTS-C is a 16-amino-acid mitochondrial-derived peptide studied for its role in metabolism, cellular stress and exercise adaptation.

What does MOTS-C stand for?

It stands for mitochondrial open-reading-frame of the 12S ribosomal RNA type-c.

Is MOTS-C naturally produced by the body?

Evidence indicates that MOTS-C is naturally produced and can be detected in tissues and blood.

Where is MOTS-C encoded?

Its proposed coding sequence is located within the mitochondrial 12S ribosomal RNA region.

Is MOTS-C a hormone?

It is sometimes described as a mitochondrial hormone or mitokine because it appears capable of signalling between cells and tissues.

Its complete physiological role is still being defined.

What is a mitokine?

A mitokine is a signalling molecule produced in response to mitochondrial activity or stress that can affect other cellular or bodily systems.

Is MOTS-C the same as humanin?

No.

Both are mitochondrial-derived peptides, but they have different amino-acid sequences and biological research profiles.

Is MOTS-C the same as a GLP-1 medicine?

No.

MOTS-C does not belong to the established GLP-1 receptor-agonist class.

Does MOTS-C activate AMPK?

Preclinical research shows that MOTS-C can activate AMPK through effects involving folate and purine metabolism.

Is AMPK a fat-burning switch?

That description is an oversimplification.

AMPK coordinates many energy-related pathways, but its activation does not automatically cause substantial fat loss.

Does MOTS-C enter the nucleus?

Laboratory research shows that metabolic stress can cause MOTS-C to enter the cell nucleus and affect stress-responsive gene expression.

Does MOTS-C change DNA?

It may change the expression of selected genes, but it has not been shown to rewrite a person’s DNA sequence.

Does exercise increase MOTS-C?

Several human studies report increased circulating or muscle-associated MOTS-C after exercise.

Does MOTS-C improve exercise performance?

It has improved physical performance in mice.

Reliable performance benefits from externally administered MOTS-C have not been established in humans.

Is MOTS-C an exercise mimetic?

It is an exercise-responsive peptide that reproduces selected exercise-associated effects in experimental models.

It does not recreate all physical and psychological benefits of exercise.

Does MOTS-C increase endurance?

Mouse studies report improvements in endurance-related performance.

Controlled human evidence remains insufficient.

Does MOTS-C increase energy?

It affects metabolic pathways in experimental models, but it is not a conventional stimulant and has not been proven to improve subjective human energy.

Does MOTS-C improve recovery?

There is insufficient controlled human evidence to establish faster recovery from exercise, injury or illness.

Does MOTS-C reduce fatigue?

This has not been established in controlled human trials.

Fatigue has many causes and should not automatically be attributed to mitochondrial dysfunction.

Does MOTS-C improve insulin sensitivity?

It improves insulin sensitivity in several mouse models.

Therapeutic improvement in humans has not yet been established.

Does MOTS-C lower blood sugar?

It influences glucose uptake and regulation in preclinical models.

Its effect on human blood glucose after external administration remains uncertain.

Does MOTS-C treat diabetes?

No MOTS-C product is approved to treat diabetes.

Does MOTS-C cause weight loss?

Substantial human weight loss has not been demonstrated.

The frequently cited evidence concerns prevention of diet-induced weight gain in mice.

Does MOTS-C burn fat?

It may influence fuel metabolism, but it has not been clinically established as a human fat-burning treatment.

Does MOTS-C suppress appetite?

Appetite suppression is not its primary established mechanism, and strong human evidence is lacking.

Does MOTS-C increase metabolism?

It affects metabolic regulation in cells and animals.

That is not the same as proving a clinically meaningful increase in human resting metabolic rate.

Does MOTS-C build muscle?

There is insufficient human evidence that it produces significant muscle growth.

Does MOTS-C reduce myostatin?

Animal research reports reduced elevated myostatin-related signalling in certain metabolic models.

Human muscle-building effects have not been demonstrated.

Does MOTS-C prevent muscle loss?

It is being investigated in relation to muscle metabolism and age-associated decline, but it is not an established treatment for sarcopenia.

Does MOTS-C improve mitochondrial health?

It affects mitochondrial-related signalling and metabolic adaptation in experimental models.

“Mitochondrial health” is broad, and human clinical benefit has not been established.

Does MOTS-C create new mitochondria?

Research suggests it may influence pathways involved in mitochondrial adaptation.

It has not been proven to cause a clinically meaningful increase in human mitochondrial number.

Does MOTS-C reverse mitochondrial damage?

No reliable human evidence supports this broad claim.

Does MOTS-C slow ageing?

It has produced healthspan-related effects in mice, but human ageing has not been shown to slow.

Does MOTS-C extend lifespan?

There is no reliable evidence that it extends human lifespan.

Does MOTS-C improve heart health?

Preclinical studies report potentially beneficial vascular and cardiac effects.

There is no large human trial showing prevention of cardiovascular events.

Does MOTS-C improve brain function?

Animal studies are preliminary. It is not an established treatment for cognitive or neurological disorders.

Does MOTS-C improve bone density?

Preclinical studies have examined bone metabolism, but clinical osteoporosis benefits have not been established.

Does MOTS-C reduce inflammation?

It changes inflammatory signalling in experimental models.

This does not establish it as a general anti-inflammatory treatment.

Does MOTS-C treat cancer?

No.

It is not an approved cancer treatment, and its effects may differ between tumour types.

Is MOTS-C approved in the UK?

No.

Has MOTS-C been studied in humans?

Yes, mainly through observational and exercise-response studies. Controlled therapeutic evidence remains limited.

Is there an established MOTS-C dose for humans?

No authorised therapeutic dose has been established.

What is the half-life of MOTS-C?

A definitive human half-life for native MOTS-C has not been established in accessible peer-reviewed pharmacokinetic research.

Can a mouse dose be converted to a human dose?

A mathematical conversion does not establish safety or effectiveness and should not replace regulated clinical development.

Is MOTS-C prohibited in sport?

Yes.

It is included on the World Anti-Doping Agency Prohibited List.

Can MOTS-C cause hypoglycaemia?

Its glucose-related mechanisms create a theoretical concern, particularly alongside diabetes medication, but the true human risk is not well defined.

Is MOTS-C safe?

There is not enough controlled human evidence to establish its complete safety profile.

Is MOTS-C safe during pregnancy?

Pregnancy and reproductive safety have not been adequately established.

Can MOTS-C interact with medicines?

Formal interaction studies are lacking.

Interactions are theoretically possible with treatments affecting glucose, metabolism or cardiovascular function.

Does purity prove MOTS-C is safe?

No.

Purity does not prove identity, correct quantity, sterility, endotoxin control, stability or clinical safety.

Is MOTS-C clinically proven?

Its biology is supported by laboratory and animal evidence, and natural MOTS-C has been measured in humans.

Therapeutic effectiveness has not yet been established through a mature human clinical-trial programme.

Research in context

What do we know with reasonable confidence?

• MOTS-C is a 16-amino-acid mitochondrial-derived peptide.

• Its proposed coding sequence lies within mitochondrial DNA.

• It influences cellular metabolism in experimental systems.

• It can activate pathways involving AMPK.

• Under metabolic stress, it can move into the nucleus and affect gene expression.

• It improves glucose regulation in several mouse models.

• It reduces high-fat-diet-associated weight gain in mice.

• Exercise can increase endogenous MOTS-C in humans.

• Experimental treatment improves physical performance in mice of different ages.

• MOTS-C is prohibited in regulated sport.

• It is not an authorised UK medicine.

What remains uncertain?

• Its normal physiological concentration across different populations

• Its exact receptor or complete molecular target network

• How mitochondrial MOTS-C RNA is exported and translated

• Its human pharmacokinetics

• Its human half-life

• Safe systemic exposure

• Whether it improves human insulin sensitivity

• Whether it improves human exercise performance

• Whether it causes clinically meaningful human weight loss

• Its long-term immune effects

• Reproductive safety

• Cancer-related effects

• Whether analogues reproduce the biology of native MOTS-C

• Whether animal healthspan effects translate to humans

What should readers be cautious about?

• “Exercise in a vial” descriptions

• Human claims based on mouse treadmill experiments

• Weight-loss claims based on prevention of mouse weight gain

• Precise dosing schedules without an approved product

• Unreferenced half-life estimates

• Claims that MOTS-C repairs mitochondrial DNA

• Claims that AMPK activation guarantees fat loss

• Treating associations in blood tests as proof of causation

• Confusing native MOTS-C with modified pharmaceutical analogues

• Assuming natural origin proves injection safety

• Ignoring its status under anti-doping rules

Key takeaways

MOTS-C is a 16-amino-acid peptide encoded by a short open-reading frame within mitochondrial DNA.

It belongs to a group of mitochondrial-derived peptides thought to help mitochondria communicate with the cell nucleus and other tissues.

The original research found that MOTS-C influenced folate and purine metabolism, activated AMPK and increased glucose use in skeletal muscle.

In mice, MOTS-C reduced high-fat-diet-associated weight gain and improved insulin sensitivity.

Later research showed that MOTS-C can enter the nucleus during metabolic stress and alter stress-responsive gene expression.

Exercise appears to increase endogenous MOTS-C in humans.

Experimental MOTS-C treatment has improved physical performance and metabolic adaptation in young, middle-aged and older mice.

These results do not establish MOTS-C as a replacement for exercise, a proven fat-loss treatment or a human anti-ageing medicine.

Human intervention evidence remains limited, and studies measuring natural MOTS-C levels have produced inconsistent results.

A definitive therapeutic dose, human half-life, long-term safety profile and approved medical use have not been established.

MOTS-C is not an authorised medicine in the United Kingdom and is prohibited under current World Anti-Doping Agency rules.

The scientifically accurate position is that MOTS-C is a promising mitochondrial signalling molecule with substantial preclinical evidence but limited proof of therapeutic benefit in humans.

Glossary

AICAR: A metabolic intermediate capable of activating AMPK when it accumulates within cells.

Amino acid: A chemical building block used to form peptides and proteins.

AMP: Adenosine monophosphate, a molecule associated with lower cellular energy availability.

AMPK: AMP-activated protein kinase, an enzyme complex involved in cellular energy sensing.

ATP: Adenosine triphosphate, the main immediately usable energy molecule in cells.

Casein kinase 2: A protein kinase involved in numerous signalling and metabolic processes.

Cytoplasm: The material inside a cell but outside the nucleus.

De novo purine synthesis: The cellular pathway used to create purines from smaller molecular components.

Endogenous: Produced naturally within the body.

Exercise mimetic: A compound intended to reproduce selected biological responses to exercise.

Gene expression: The process through which genetic information is used to produce RNA or proteins.

Healthspan: The period of life spent in relatively good health and function.

Humanin: A mitochondrial-derived peptide distinct from MOTS-C.

Insulin resistance: Reduced responsiveness of tissues to insulin.

Insulin sensitivity: The effectiveness with which tissues respond to insulin.

Metabolic flexibility: The ability to switch appropriately between energy sources.

Mitochondria: Cellular structures involved in energy production, metabolism and signalling.

Mitochondrial DNA: The small genome located within mitochondria.

Mitochondrial-derived peptide: A small signalling peptide encoded by a short sequence within mitochondrial DNA.

Mitokine: A mitochondrial-associated signalling molecule capable of affecting other cells or tissues.

MOTS-C: Mitochondrial open-reading-frame of the 12S ribosomal RNA type-c.

Myostatin: A signalling protein that restrains skeletal-muscle growth.

Nuclear translocation: Movement of a molecule into the cell nucleus.

Open-reading frame: A DNA or RNA sequence with the potential to encode a peptide or protein.

Oxidative stress: An imbalance between reactive molecules and antioxidant defences.

Pharmacodynamics: The study of what a substance does to the body.

Pharmacokinetics: The study of how a substance is absorbed, distributed, metabolised and eliminated.

Purine: A molecular building block used in DNA, RNA, ATP and related molecules.

Retrograde signalling: Communication from mitochondria back to the nucleus or wider cell.

Sarcopenia: Age-associated loss of skeletal-muscle mass, strength or function.

Skeletal muscle: Muscle attached to the skeleton that enables movement and plays a major metabolic role.

Important notice

This article is provided for general scientific and educational purposes.

It is not intended to diagnose, treat or prevent any medical condition. It should not be interpreted as medical advice, prescribing guidance, performance-enhancement guidance or instructions for administering MOTS-C.

Most intervention evidence for MOTS-C comes from laboratory experiments and animal models. Human exercise studies examining naturally produced MOTS-C do not establish the safety or effectiveness of externally administered material.

MOTS-C is not an authorised UK medicine and is prohibited under current World Anti-Doping Agency rules